Iovance Biotherapeutics’ Amtagvi study data shows 49 per cent response rate for commercialisation: San Carlos, California Thursday, July 17, 2025, 12:00 Hrs [IST] Iovance Biothe ...

Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and ...

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...

Iovance Biotherapeutics has proven to be an innovative biotech. Over the past two years, Iovance Biotherapeutics (NASDAQ: ...

IOVA's ASCO update reiterates the value of Amtagvi in melanoma, but upcoming data in lung cancer and endometrial cancer in H2 ...

Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ ...

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for 297,600 shares of common stock to fifty new non-executive employees as part of its Amended and Restated 2021 ...

Iovance Biotherapeutics, Inc., et al., No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments ...

Iovance Biotherapeutics, Inc., et al., Case No. 25-cv-4199. About ClaimsFiler. ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of ...